文献速递神经免疫认知障碍与痴呆

疾病修饰治疗调节多发性硬化视网膜萎缩

Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
PubMed 文献 · Neurology · 2017-01-11

该回顾性研究纳入402例接受OCT随访的复发缓解型多发性硬化患者,分析不同疾病修饰治疗对视网膜萎缩速率的影响,发现GCIP变薄速率因治疗不同而异,支持OCT作为监测神经退行性治疗效果的指标。

要点

  • 相比那他珠单抗,干扰素β-1a皮下和醋酸格拉替雷治疗者GCIP变薄更快。
  • 干扰素β-1a皮下组治疗第一年GCIP变薄速度显著快于后续时间。
  • OCT可作为监测RRMS神经退行性治疗效果的实用指标。

核心结论

  • RRMS患者GCIP萎缩速率因DMT使用不同而异。
  • OCT可用于监测视网膜神经退行性治疗效果,并作为RRMS临床试验的实用结局指标。

研究设计与样本

  • 回顾性研究,纳入402例在约翰霍普金斯MS中心随访并接受Cirrus-HD OCT的RRMS患者。
  • 纳入标准包括至少1年OCT随访且期间坚持单一DMT。
  • 采用自动黄斑分割计算GCIP及其他视网膜层厚度,混合效应线性回归分析视网膜厚度变化。

主要发现

  • 评估了醋酸格拉替雷(n=48)、那他珠单抗(n=46)、干扰素β-1a皮下(n=35)和肌注(n=28)的效果。
  • 基线时各组年龄、性别、视神经炎史或随访时长无显著差异。
  • 调整相关因素后,相比那他珠单抗组,干扰素β-1a皮下组和醋酸格拉替雷组GCIP变薄分别快0.37 μm/y(p<0.001)和0.14 μm/y(p=0.035)。
  • 干扰素β-1a皮下组治疗第一年GCIP变薄比后续时间快1.53 μm/y(p<0.001)。

临床怎么用

  • OCT测量的GCIP厚度变化可用于监测RRMS患者对DMT的神经退行性应答。
  • 临床选择DMT时可考虑不同药物对 retinal atrophy 速率的差异影响。

局限性

  • 回顾性研究设计。
  • 仅纳入坚持单一DMT且有至少1年OCT随访的患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To retrospectively investigate whether disease-modifying therapies (DMTs) exert differential effects on rates of retinal atrophy in relapsing-remitting multiple sclerosis (RRMS), as assessed using optical coherence tomography (OCT). METHODS: A total of 402 patients with RRMS followed at the Johns Hopkins MS Center who underwent Cirrus-HD OCT were assessed for eligibility. Inclusion criteria included at least 1 year of OCT follow-up and adherence to a single DMT during the period of follow-up. Combined thickness of the ganglion cell + inner plexiform (GCIP) and other retinal layers was computed utilizing automated macular segmentation. Retinal thickness changes were analyzed using mixed-effects linear regression. RESULTS: The effects of glatiramer acetate (GA; n = 48), natalizumab (NAT; n = 46), and interferon-β-1a subcutaneously (IFNSC; n = 35) and intramuscularly (IFNIM; n = 28) were assessed. Baseline analyses revealed no significant differences between groups in terms of age, sex, optic neuritis history, or follow-up duration. During follow-up, relative to NAT-treated patients, IFNSC- and GA-treated patients exhibited 0.37 μm/y (p < 0.001) and 0.14 μm/y (p = 0.035) faster rates of GCIP thinning, respectively, adjusting for the interval between initiation of DMT and OCT monitoring (gap time), age, sex, relapses, and disease duration. In the IFNSC group, GCIP thinning was 1.53 μm/y faster during the first year of therapy vs during the time interval afterwards (p < 0.001). CONCLUSIONS: Rates of GCIP atrophy in patients with RRMS vary according to DMT utilization. Our findings support OCT for monitoring neurodegenerative treatment effects in the retina, an easily accessible tissue, and as a practical outcome measure in RRMS clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Button J, Al-Louzi O, Lang A, et al. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study. Neurology. 2017. PMID: 28077493. doi:10.1212/WNL.0000000000003582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。